Kevin Staveley-O’Carroll, MD, PhD, discusses one of the challenges in treating patients with hepatocellular carcinoma and shares what he thinks are the next steps in overcoming this challenge.
Kevin Staveley-O’Carroll, MD, PhD, surgery chair at the University of Missouri School of Medicine, and director of the Ellis Fischel Cancer Center, discusses one of the challenges in treating patients with hepatocellular carcinoma (HCC) and shares what he thinks are the next steps in overcoming this challenge.
Many different lines of therapy have been developed, but now the challenge lies in integrating these therapies properly in the treatment landscape of HCC, Staveley-O’Carroll says.
For example, by combining targeted kinase therapies with local ablative therapies, all of the dead tumor could be released, giving the patient the opportunity for more effective immunotherapy treatment.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More